Down-Regulation of miR-148a Promotes Metastasis by DNA Methylation and is Associated with Prognosis of Skin Cancer by Targeting TGIF2

Yanli Tian*
Wei Wei*
Li Li
Rongya Yang

* Yanli Tian and Wei Wei are co-first authors

Corresponding Author:
Rongya Yang, e-mail: yrongya@163.com

Source of support:
Departmental sources

Background:
MicroRNAs (miRNA) dysregulation has been considered to be significantly related to the occurrence and development of cancers. Several studies had proved that DNA methylation is an important cause of the abnormal expression of miRNAs. The purpose of this study was to investigate the methylation status of miR-148a and its effects on the metastasis and prognosis of skin cancer, as well as the interaction with TGIF2 gene.

Material/Methods:
According to the qRT-PCR analysis, the expression of miR-148a was down-regulated in tumor tissues compared with the adjacent tissues and healthy controls (P<0.05). In vitro cell metastasis assay revealed that miR-148a could inhibit cell metastasis and its down-regulation promoted metastasis. Luciferase reporter assay found that TGIF2 gene was a target gene and its expression was suppressed by miR-148a in skin cancer.

Results:
Methylation-specific PCR demonstrated that DNA methylation rate of miR-148a was higher in tumor tissues than in adjacent tissues and healthy tissues (P<0.05). miR-148a expression was proved to be epigenetically regulated after the demethylation of it by 5-aza-20-deoxycytidine treatment and qRT-PCR analysis. miR-148a methylation was significantly influenced by many clinicopathologic characteristics such as age (P=0.000), pathological differentiation (P=0.000), and lymph node metastasis (P=0.000). Besides, Kaplan-Meier analysis showed patients with miR-148a methylation lived shorter than those without that (P<0.001). Cox regression analysis manifested that miR-148a methylation (HR=0.053, 95CI%=0.005–0.548, P=0.014) could be serve as an independent prognostic marker for skin cancer.

Conclusions:
Taken together, the expression of miR-148a was regulated by DNA methylation and targeted by TGIF2. Its methylation may be a potential prognostic indicator in skin cancer.

MeSH Keywords:
Genes, Tumor Suppressor • Methylation • MicroRNAs • Prognosis • Skin Neoplasms

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/894826
Background

Skin cancers are one of the most common seen malignancies in human (1). Among them, non-melanoma skin cancer accounts for 10% of all cancer types and for less than 0.1% of cancer-related deaths [1,2]. The incidence of skin cancers has been increasing year by year and 2.75 million new cases in the worldwide annually [3,4]. Melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) are the main types of skin cancers [5]. And there are many risk factors for the incidence and development of skin cancer such as ultraviolet light exposure, age, male gender, genetic susceptibility, phenotypic features and immunity have been reported [6,7]. However, the pathogenesis of skin cancer has not been fully elucidated. Epigenetic alterations in multiple genes are believed to play crucial roles in skin carcinogenesis. The study of the fundamental mechanism of DNA methylation may be helpful to understand the progression of skin cancer.

MicroRNAs (miRNAs) are a class of small non-coding RNA molecules with a length of 18–25 nucleotides. They have been confirmed to be related to progression of various cancers via acting as an oncogene or tumor suppressor and other roles. miRNAs also can regulate gene expression by specific sites within the 3’-Untranslated Regions (3’-UTR) of a target-mRNA at post transcriptional level [8]. Besides, they participate in many processes of diseases such as cell growth, cell cycle, apoptosis, migration and invasion [9]. The deregulated of miRNAs haven been confirmed to play vital role in various disease including cancers in previous studies. miR-148a had been considered to be a tumor suppressor in various of cancers including gastric, non-small cell lung, colorectal cancer, liver cancer, pancreatic cancer, breast cancer, osteosarcoma and so on [10–16]. Amaia et al., proved that TGIF2 was a target gene of miR-148a [17]. Nevertheless, the interaction of miR-148a and TGIF2 as well as their role in skin cancer had never been covered. Besides, DNA methylation has also been found to regulate the expression of miR-148a in several studies [18–20]. However, whether the expression of miR-148a in skin cancer is related to DNA methylation remains unknown.

In this study, we investigated the expression level of miR-148a and its methylation status in skin cancer. At the same time, we explored the relationship between miR-148a and TGIF2. In addition, the association between miR-148a and the prognosis of skin cancer was also detected. And these were expected to provide a new prognostic marker and therapy for this disease.

Material and Methods

Patients and samples

The current study was conducted in The General Hospital of Beijing Military Command and was permitted by the Ethics Committee of the hospital. 105 patients diagnosed as skin cancer were included. All the patients had never received any chemical treatment and physical therapy before sampling. Besides, 89 healthy people were taken as normal controls. Written informed consents were signed by each participant in advance.

Tumor tissues, adjacent tissues, and healthy tissues were collected from the patients with skin cancer and healthy people, respectively. Liquid nitrogen was used to immediately freeze the samples. Then the samples were stored at –80°C for later use. Clinicopathologic characteristics, such as age, sex, tumor thickness, tumor subtype, pathological differentiation, lymph node metastasis, and clinical stage, were recorded in a database. The follow-up was performed with a telephone interview or questionnaire for 5 years. The overall survival was defined as the day of surgery to the day of death. Patients who died from unexpected events or other diseases were excluded in our study.

Quantitative real-time polymerase chain reaction (QRT-PCR)

Total RNA was extracted from the patients with skin cancer and healthy controls with TRIzol (Invitrogen, Carlsbad, CA, USA). The reverse transcription was made to synthesize the first chain of cDNA with TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Then RT-PCR reaction was performed in the Applied Biosystems 7900 Fast Real-Time PCR system (Applied Biosystems, Foster City, California, USA). GAPDH was taken as the internal control. The relative expression quantification of miR-148a at mRNA level was evaluated by comparative cycle threshold (CT) method.

Enzyme-linked immunosorbent assay (ELISA)

Total protein was isolated from the tumor tissues, adjacent normal tissues, and healthy tissues. Then the levels of TGIF2 were determined by a commercial reagent kit following the manufacturer’s instructions.

Luciferase reporter assays

The wild- or mutant-type 3’-UTR of TGIF2 was inserted into the pcDNA3.1/HisC vector (Invitrogen, Carlsbad, CA). Cells were seeded in 24-well plates for 24 h before transfection. Then the cells were transfected with the reporter vector (pcDNA3.1/HisC-TGIF2-WT-3’UTR or pcDNA3.1/HisC-TGIF2-MT-3’UTR) and miR-148a mimics or scrambled mimics using Lipofectamine 2000
MOLECULAR BIOLOGY

PCR was: initial denaturation at 95°C for 15 min, 45 cycles respectively, 0.1 μl 5U/μl Taq Gold polymerase and sterile water, 2.5 μl dNTPs, 2.5 μl forward and reverse primer respectively, contained 2 μl Modified DNA, 2.5 μl 10×PCR buffer, 2.5 μl MgCl₂ solution, 2.5 μl dNTPs, 2.5 μl forward and reverse primer respectively, 0.1 μl 5U/μl Taq Gold polymerase and sterile water which was supplied to total 25 μl. The procedure of MS-PCR was: initial denaturation at 95°C for 15 min, 45 cycles of denaturation for 30 s at 95°C, annealing at 55°C for 45 s, extension at 72°C for 30 s, and extension at 72°C for 5 min.

**Lentivirus infection and siRNAs**

Lentiviruses containing miR-148a (LV-miR-148a) and negative control (LV-NC) were purchased from GeneChem (Shanghai, China). When the concentration of cells reached to 70%, the LV-miR-148a or negative control lentivirus were added. Six days later, the expressions of miR-148a and TGIF2 were detected by qRT-PCR and ELISA, respectively.

**Cell culture and cell metastasis assays**

Human skin cancer cell lines A431 were obtained from the Pasteur institute of Iran and cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. The mediums were maintained at 37°C in a humidified atmosphere containing 5% CO₂. Cell metastasis was assessed by wound-healing assay. A confluent cell monolayer without FBS was scratched artificially using sterile tips, and wound-healing images were taken at 24 and 48 h later.

**DNA extraction and bisulfite modification**

Genomic DNA was extracted from the tumor tissues, adjacent tissues and healthy controls with the DNA Mammalian Genomic Purification Kit purchased from Sigma-Aldrich Co. (St. Louis, MO). Then the DNA was treated with sodium bisulfite using the EZ DNA Methylation TM Kit (Zymo Research, Orange, CA) to conduct the conversion of cytosine to uracil. The modified DNA was resuspended in elution buffer and stored at –20°C.

**Methylation-specific polymerase chain reaction (MSP)**

The modified DNA was used to analyze the methylation status of miR-148a in skin cancer using methylation-specific polymerase chain reaction on the ABI7500 PCR system (ABI Co, Norwalk, Connecticut) with the SYBR Premix Taq ExTaq Kit (TaKaRa Co Ltd, Otsu, Shiga, Japan). The primer for the methylated miR-148a and unmethylated sequences were as follows: methylated, forward-5′-TACGGGAGGTTCTGTAACGC-3′, reverse-5′-CACGAAACGAAATTCGAA-3′; unmethylated, forward-5′-TTTGTAGGGGAGGTTTGCAGTTAAGG-3′, reverse-5′-CAAAACAATATTCAAAACT-3′. The PCR amplification system contained 2 μl Modified DNA, 2.5 μl 10×PCR buffer, 2.5 μl MgCl₂ solution, 2.5 μl dNTPs, 2.5 μl forward and reverse primer respectively, 0.1 μl 5U/μl Taq Gold polymerase and sterile water which was supplied to total 25 μl. The procedure of MS-PCR was: initial denaturation at 95°C for 15 min, 45 cycles of denaturation for 30 s at 95°C, annealing at 55°C for 45 s, extension at 72°C for 30 s, and extension at 72°C for 5 min.

**DNA extraction and bisulfite modification**

**DNA extraction and bisulfite modification**

Genomic DNA was extracted from the tumor tissues, adjacent tissues and healthy controls with the DNA Mammalian Genomic Purification Kit purchased from Sigma-Aldrich Co. (St. Louis, MO). Then the DNA was treated with sodium bisulfite using the EZ DNA Methylation TM Kit (Zymo Research, Orange, CA) to conduct the conversion of cytosine to uracil. The modified DNA was resuspended in elution buffer and stored at –20°C.

**Methylation-specific polymerase chain reaction (MSP)**

The modified DNA was used to analyze the methylation status of miR-148a in skin cancer using methylation-specific polymerase chain reaction on the ABI7500 PCR system (ABI Co, Norwalk, Connecticut) with the SYBR Premix Taq ExTaq Kit (TaKaRa Co Ltd, Otsu, Shiga, Japan). The primer for the methylated miR-148a and unmethylated sequences were as follows: methylated, forward-5′-TACGGGAGGTTCTGTAACGC-3′, reverse-5′-CACGAAACGAAATTCGAA-3′; unmethylated, forward-5′-TTTGTAGGGGAGGTTTGCAGTTAAGG-3′, reverse-5′-CAAAACAATATTCAAAACT-3′. The PCR amplification system contained 2 μl Modified DNA, 2.5 μl 10×PCR buffer, 2.5 μl MgCl₂ solution, 2.5 μl dNTPs, 2.5 μl forward and reverse primer respectively, 0.1 μl 5U/μl Taq Gold polymerase and sterile water which was supplied to total 25 μl. The procedure of MS-PCR was: initial denaturation at 95°C for 15 min, 45 cycles of denaturation for 30 s at 95°C, annealing at 55°C for 45 s, extension at 72°C for 30 s, and extension at 72°C for 5 min.

**5-Aza-dC treatment**

To analyze the influence of miR-148a methylation on the expression of miR-148a and TGIF2 protein, A431 cells were treated with 5-aza-20-deoxycytidine (5-Aza-dC, Sigma-Aldrich, USA) to do the demethylation study. The dose of 5-Aza-dC was 0.5 mmol/l and the time lasted for 4 days while the culture medium containing 5-Aza-dC was replaced every 24 h.

**Results**

**The down-regulated of miR-148a in patients with skin cancer at mRNA level**

The expression of miR-148a was detected by qRT-PCR at the mRNA level. The result demonstrated that its expression was significantly lower in tumor tissues than in adjacent normal tissues and healthy tissues (Figure 1, P<0.05). This revealed that miR-148a is a tumor suppressor in skin cancer.

**miR-148a inhibits the cell metastasis**

To further understand the function of miR-148a in skin cancers, we made a wound-healing assay to estimate its effects on cell metastasis. The outcome proved that the down-regulation of miR-148a induced the metastasis of skin cancer cells compared to the controls (Figure 2). In contrast, the cell metastasis was inhibited when the endogenous miR-148a was silenced. These results suggest that miR-148a might function as a tumor suppressor by promoting cell metastasis in skin cancer cells.
miR-148a directly targets TGIF2 and inhibits its expression in skin cancer in vitro

To elucidate the molecular mechanism by which miR-148a exerts its inhibitory effect on skin cancer cells, we measured the expression of TGIF2 which was predicted as potential targets of miR-148a. ELISA assay showed that the expression of TGIF2 protein was down-regulated in tumor tissues compared with those in adjacent tissues and healthy tissues (Figure 3, P<0.05). Then, we estimated the correlation between the expression of miR-148a and TGIF2, a positive correlation was shown (Figure 4). A luciferase reporter assay was further performed to verify whether miR-148a directly targets TGIF2 gene in skin cancer cells. The wild-TGIF2 and mutant-TGIF2 containing the predicted binding sites of miR-148a were constructed and cloned downstream to a luciferase reporter, respectively. Then these two vectors were co-transfected with miR-148a mimics, miR-148a inhibitor (anti-miR-148a mimics), or their respective scrambled controls into A431 cells. The result indicated that transfection of miR-148a mimics significantly decreased the luciferase activity of cells (Figure 5). Moreover, the luciferase activity which was mediated by miR-148a was suppressed by the mutant putative binding sites. These findings support the hypothesis that TGIF2 is a direct target gene for miR-148a in skin cancer cells.

Knock-down of TGIF2 contributes to cell migration of skin cancer cells in vitro

The TGIF2 was knocked-down to analyze its function in skin cancer by TGIF2-specific small interfering RNAs (si-TGIF2) and was confirmed by ELISA (Figure 6A). Then we performed
transwell assays with wound-healing assays, which clarified that knockdown of TGIF2 in skin cancer cells could significantly inhibit cell migration ability (Figure 6B). This effect was as same as the down-regulation of miR-148a.

The expression of miR-148a is epigenetically regulated by DNA methylation in skin cancer cells

MSP was carried out to observe the methylation of miR-148a in skin cancer cells. The A431 cells were treated with 5-Aza-dC, a demethyltransferase inhibitor, showing that the expression of miR-148a was up-regulated after the 5-Aza-dC treatment compared with those without treatment). We found that DNA methylation in miR-148a frequently occurred in 85 tumor tissues (55 partially methylated and 30 completely methylated), while the adjacent tissues and healthy controls were all unmethylated (Figure 7). This suggests that epigenetic factors can affect the expression of miR-148a, and that DNA methylation might be an important mechanism in the function of miR-148a on skin cancer.

The relationship between miR-148a methylation and clinicopathologic characteristics

the above assays showed that miR-148a methylation might be a participator of the development of skin cancer. Therefore, we estimated the relationship between miR-148a methylation and clinicopathologic characteristics to prove our inference. As shown in Table 1, age (P=0.000), pathological differentiation (P=0.000), and lymph node metastasis (P=0.000) were considered to be vital influential factors to the methylation of miR-148a, which provided strong support for our view above.

The association between miR-148a methylation and overall survival

To make sure the prognostic value of miR-148a methylation in skin cancer, we concluded the follow-up information and analyzed its role in prognosis via Kaplan-Meier and Cox regression analysis, respectively. Kaplan-Meier analysis showed that the overall survival of patients with miR-148a methylation was shorter than in those without miR-148a methylation (Figure 8, log rank test, P<0.001). The clinicopathologic characteristics, such as tumor thickness (HR=0.359, 95CI%=0.150–0.861, P=0.022), lymph node metastasis (HR=0.364, 95CI%=0.086–0.810, P=0.020), and clinical stage (HR=0.417, 95CI%=0.186–0.935, P=0.034), were proved to be related to the prognosis of skin cancer as well as miR-148a methylation (HR=0.053, 95CI%=0.005–0.548, P=0.014) and they might be independent prognostic indicators in skin cancer (Table 2).

Discussion

Numerous reports had reported that miRNAs act as important regulator in about one-third of human coding genes at the post-transcription level and plays a crucial role in most tumor
miR-148a has been shown to have aberrant expression in several cancers and it is considered to be an important tumor suppressor in these cancers. It was also found to be down-regulated in melanoma [22]. In this study, we detected the expression of miR-148a in 105 patients with skin cancer and 89 healthy controls. The expression of miR-148a was significantly lower in tumor tissues compared with adjacent tissues and healthy tissues, which is consistent with the trend in melanoma. In addition, TGIF2 was thought to be a target gene of miR-148a. Therefore we validated this view according to measure the expression of TGIF protein and the expression of miR-148a when the TGIF2 knocked down. The experimental illuminated that TGIF2 gene was one of the targeted gene and its expression was mediated by miR-148a which was agree with the point before [17].

Epigenetic modifications are a main cause of abnormal gene expression, including some miRNAs [23–25]. The aberrant DNA methylation of miRNA plays a significant role in cancer

| Clinicopathologic characteristics | n | miR-148a methylation | P |
|-----------------------------------|---|----------------------|---|
|                                   |   | Methylated | Unmethylated |
| Age                               |   |            |              |
| ≤60                               | 78 | 33         | 45           |
| >60                               | 27 | 22         | 5            |
| Sex                               |   |            |              |
| Female                            | 30 | 18         | 12           |
| Male                              | 75 | 37         | 38           |
| Tumor thickness                   |   |            |              |
| ≤2 cm                             | 57 | 25         | 32           |
| >2 cm                             | 48 | 30         | 18           |
| Tumor subtype                     |   |            |              |
| SSM                               | 29 | 16         | 13           |
| LMM                               | 42 | 21         | 21           |
| Others                            | 34 | 18         | 16           |
| Pathological differentiation      |   |            |              |
| Low                               | 54 | 18         | 36           |
| High + moderate                   | 51 | 37         | 14           |
| Lymph node metastasis             |   |            |              |
| No                                | 60 | 20         | 40           |
| Yes                               | 45 | 35         | 10           |
| Clinical stage                    |   |            |              |
| I+II                              | 45 | 21         | 24           |
| III+IV                            | 60 | 34         | 26           |

Table 1. The relationship between miR-148a methylation and Clinicopathologic Characteristics of patients with skin cancer.

Figure 8. Kaplan-Meier analysis for patients with skin cancer and the miR-148a methylation.

formation and development [21], miR-148a has been shown to have aberrant expression in several cancers and it is considered to be an important tumor suppressor in these cancers. It was also found to be down-regulated in melanoma [22]. In this study, we detected the expression of miR-148a in 105 patients with skin cancer and 89 healthy controls. The expression of miR-148a was significantly lower in tumor tissues compared with adjacent tissues and healthy tissues, which is consistent with the trend in melanoma. In addition, TGIF2 was thought to be a target gene of miR-148a. Therefore we validated this view according to measure the expression of TGIF protein and the expression of miR-148a when the TGIF2 knocked down. The experimental illuminated that TGIF2 gene was one of the targeted gene and its expression was mediated by miR-148a which was agree with the point before [17].

Epigenetic modifications are a main cause of abnormal gene expression, including some miRNAs [23–25]. The aberrant DNA methylation of miRNA plays a significant role in cancer
progression [26,27]. To make determine the influential factors of the down-regulation of miR-148a, we detected the methylation status of miR-148a in skin cancer and analyzed whether its status could influence the expression of miR-148a. Firstly, we tested the methylation status of miR-148a by MSP and verified that miR-148a methylation rate was higher in tumor tissues than in adjacent tissues and healthy tissues. Then 5-Aza-dC was added into skin cancer cells for demethylation, and after that the expression of miR-148a was increased in tumor tissues compared with the expression before demethylation via qRTPCR. These revealed that the methylation might be the mechanism of the down-regulation of miR-148a.

Metastasis is responsible for 90% of deaths in patients with solid tumors, especially lymphatic route of metastasis [28–30]. Several miRNAs had been confirmed to be linked with the metastasis of tumors such as miR-10b, miR-373, miR-126 and miR-335 in some cancers [31–33]. miR-148a was also found to be significantly associated with the appearance of lymph node metastasis in human cancer [17]. Our findings indicated that DNA methylation-associated down-regulation of miR-148a could contribute to the metastasis of skin cancer by targeting with TGIF2 gene.

### References:

1. Jemal A, Bray F, Center MM et al: Global cancer statistics. Cancer J Clin, 2011; 61: 69–90  
2. de Giorgi V, Grazzini M, Gori A et al: ABO blood group and risk of cutaneous malignant melanoma. Eur J Cancer Prev, 2011; 20: 121–22  
3. Cihan YB, Baykan H, Kavuncuoglu E et al: Relationships between skin cancers and blood groups – link between non-melanomas and ABO/Rh factors. Asian Pac J Cancer Prev, 2013; 14: 4199–203  
4. Marcil I, Stern RS: Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol, 2000; 136: 1524–30  
5. Xie J, Qureshi AA, Li Y, Han J: ABO blood group and incidence of skin cancer. PLoS One, 2010; 5: e11972  
6. Han J, Colditz GA, Hunter DJ: Risk factors for skin cancers: a nested case-control study within the Nurses’ Health Study. Int J Epidemiol, 2006; 35: 1514–21  
7. Baykan H, Cihan YB, Ozyurt K: Roles of white blood cells and subtypes as inflammatory markers in skin cancer. Asian Pac J Cancer Prev, 2015; 16: 2303–6  
8. Wang X, Wang ZH, Wu YY et al: Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway. Mol Neurobiol, 2013; 47: 373–81  
9. Bushati N, Cohen SM: microRNA functions. Annu Rev Cell Dev Biol, 2007; 23: 175–205  
10. Wang SH, Li X, Zhou LS et al: microRNA-148a suppresses human gastric cancer cell metastasis by reversing epithelial-to-mesenchymal transition. Tumour Biol, 2013; 34: 3705–12  
11. Li J, Song Y, Wang Y et al: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem, 2013; 380: 277–82  
12. Takahashi M, Cuatrecasas M, Balaguer F et al: The clinical significance of miR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One, 2012; 7: e66848  
13. Gailhouste L, Gomez-Santos L, Hagiwara K et al: miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology, 2013; 58: 1153–65

### Table 2. Multivariate analysis for the prognostic factor of patients with skin cancer.

| Parameter               | Risk ratio | 95% confidence interval | P value |
|-------------------------|------------|-------------------------|---------|
| Tumor thickness         | 0.359      | 0.150–0.861             | 0.022   |
| Lymph node metastasis   | 0.264      | 0.086–0.810             | 0.020   |
| Clinical stage          | 0.417      | 0.186–0.935             | 0.034   |
| miR148a methylated      | 0.053      | 0.005–0.548             | 0.014   |
| miR-148a unmethylated   | –          | –                       | –       |

To explore the function of methylation in miR-148a, the relationship between the expression of this miRNA and clinicopathologic characteristics, as well as overall survival of patients with skin cancer, were estimated. The methylation of miR-148a was clearly impacted by age, pathological differentiation, and lymph node metastasis in our study. Kaplan-Meier analysis revealed patients with miR-148a methylation had a much shorter overall survival than those without this condition. Moreover, cox regression analysis adjusted for clinicopathologic characteristics demonstrated that tumor thickness, lymph node metastasis, clinical stage, and miR-148a methylation were independent prognostic factors in skin cancer.

### Conclusions

The expression of miR-148a is decreased in patients with skin cancer by targeting with TGIF2. Its expression is a promoter for the metastasis of skin cancer cells. Meanwhile, the expression and function of miR-148a are regulated by DNA methylation, and its methylation can be an independent indicator in the prognosis of skin cancer. However, due to the limitation of the number of samples and experimental conditions, as well as other unfavorable factors, further studies are still necessary.
14. Schultz NA, Andersen KK, Roslind A et al: Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer – five microRNAs in a prognostic index. World J Surg, 2012; 36: 2699–707
15. Aydogdu E, Katchy A, Tsouko E et al: MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis, 2012; 33: 1502–11
16. Ma W, Zhang X, Chai J et al: Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. Tumour Biol, 2014; 35: 12467–72
17. Lujambio A, Calin GA, Villanueva A et al: A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA, 2008; 105: 13556–61
18. Zhu A, Xia J, Zuo J et al: MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer. Med Oncol, 2012; 29: 2701–9
19. Li HP, Huang HY, Lai YR et al: Silencing of miR-148a by hypermethylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma. Oncotarget, 2014; 5: 7610–24
20. Hanoun N, Delpu Y, Surlawinata AA et al: The silencing of microRNA 148a production by DNA methyltransferase 1 in pancreatic cancer. Clin Chem, 2010; 56: 1107–18
21. Yang Y, Huang JQ, Zhang X, Shen LF: MiR-129-2 functions as a tumor supressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. Mol Cell Biochem, 2015; 404: 229–39
22. Haflidadottir BS, Bergsteindottir K, Praetorius C, Steingrimsson E: miR-148 regulates Miff in melanoma cells. PLoS One, 2010; 5: e11574
23. Nguyen T, Kuo C, Nicholl MB et al: Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics, 2011; 6: 388–94
24. Datta J, Kutay H, Nasser MW et al: Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res, 2008; 68: 5049–58
25. Bracconi C, Huang N, Patel T: MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology, 2010; 51: 881–90
26. Jones PA, Baylin SB: The epigenomics of cancer. Cell, 2007; 128: 683–92
27. Ellis L, Atadja PW, Johnstone RW: Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther, 2009; 8: 1409–20
28. Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer, 2003; 3: 453–58
29. Gupta GP, Massague J: Cancer metastasis: building a framework. Cell, 2006; 127: 679–95
30. Jackson DG: Lymphatic markers, tumour lymphangiogenesis and lymph node metastasis. Cancer Treat Res, 2007; 135: 39–53
31. Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 2007; 449: 682–88
32. Huang Q, Gumireddy K, Schrier M et al: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol, 2008; 10: 202–10
33. Tavazoie SF, Alarcon C, Oskarsson T et al: Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 2008; 451: 147–52